1.
Open Forum Infect Dis
; 9(7): ofac282, 2022 Jul.
Article
in English
| MEDLINE
| ID: mdl-35859992
ABSTRACT
We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients.